IDXG Interpace Biosciences

Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated

Interpace Biosciences’ Audit Committee Investigation Finds Complaints Unsubstantiated
EN
14/10/2020

Underlying

IDXGInterpace Biosciences

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Interpace Biosciences

 PRESS RELEASE
Free
IDXG Interpace Biosc...

Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue...

Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free balance sheet and positive Net Income and EBITDA operations Company to seek uplisting on the Nasdaq Stock Market PARSIPPANY, NJ, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced preliminary and unaudited 2025 r...

January 20, 2026 1 EN
 PRESS RELEASE
Free
IDXG Interpace Biosc...

Interpace Biosciences Announces Early Repayment of Debt to BroadOak Ca...

Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners PARSIPPANY, NJ, Dec. 03, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced that it has fully repaid its outstanding term loan facility with BroadOak Capital Partners (“BroadOak”) prior to the facility’s maturity date. The repayment satisfies the Company’s obligations under the Loan and Security Agreement originally entered into on October 29, 2021, with BroadOak Fund V, L.P. By retiring this debt early, Interpace eliminates related interest ...

December 3, 2025 1 EN
 PRESS RELEASE
Free
IDXG Interpace Biosc...

Interpace Biosciences Announces Third Quarter 2025 Financial and Busin...

Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results  ●Q3 Revenue of $8.8 million ●Q3 Cash Collections of $10.0 million ●Q3 Thyroid test volume up 12% year-over-year to record levels ●Q3 Thyroid revenue of $8.8M; up 22% year-over-year to record levels    PARSIPPANY, NJ, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the third quarter ended September 30, 2025 and provided a business and financial update. Third quarter Net Revenue was $8.8 million. Income from cont...

November 12, 2025 1 EN
 PRESS RELEASE
Free
IDXG Interpace Biosc...

Interpace Biosciences Presented Two New Posters at the 2025 American T...

Interpace Biosciences Presented Two New Posters at the 2025 American Thyroid Association® (ATA) Annual Meeting Highlights Independent institutional experience shows archival cytology slides enabled successful molecular results in cases previously insufficient for testing by another commercially available molecular diagnostic test, helping avoid repeat FNAsLarge real-world analysis (n=28,144) demonstrates how ThyGeNEXT® + ThyraMIR®v2 refines risk in Bethesda III/IV nodules, especially in RAS-like and mutation-negative casesPresentations were held during the ATA Annual Meeting, September 10–...

September 15, 2025 1 EN
 PRESS RELEASE
Free
IDXG Interpace Biosc...

Interpace Biosciences Announces Second Quarter 2025 Financial and Busi...

Interpace Biosciences Announces Second Quarter 2025 Financial and Business Results  ●Q2 Revenue of $9.2 million ●Q2 Cash Collections of $10.8 million ●Q2 Thyroid test volume up 16% year-over-year to record levels ●Q2 Thyroid revenue of $8.7M; up 25% year-over-year to record levels PARSIPPANY, NJ, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG) today announced financial results for the second quarter ended June 30, 2025 and provided a business and financial update. Second quarter Net Revenue was $9.2 million. Loss from continuing ...

August 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch